Novetide is involved
in research and development of technologies for the preparation of improved
peptide based active pharmaceutical ingredients for the pharmaceutical industry.
It offers a list of commercial products as well as its experience for the development
of your proprietary peptide.
Novetide was established in 1992, initially as a business unit within IMI, the corporate R&D center of Israel Chemicals (ICL). From 1999, Novetide is an independent company.
Novetide
means flexibility,
with a choice of state-of-the-art R&D laboratories, pilot plant and cGMP
production facilities. We have the capacity, technology and all appropriate
facilities to meet your needs.
R&D and pilot plant are located within the IMI complex, where sophisticated organic chemistry is routinely practiced. Novetide's proximity to this complex provides us with powerful tools for development of overall synthetic routes to peptide and peptidomimetic compounds, including full process development, analytical R&D and methods validation, and preparation of qualification lots.
A State-of-the-art Production plant at TevaTech, Ramat Hovav, operates under strict cGMP compliance and has an excellent record. This production facility has the capacity to produce peptide APIs in multi-kg. lots.
As a prominent supplier for the
pharmaceutical industry, via our comprehensive technology platform, our foremost
commitment is to your peptide APIs. It is our continuing commitment to improve
performance and deliver top service to our customers.
Dr. Avi Tovi, President and CEO
Dr. Chaim Eidelman, CTO
Mr. Dov Hirshenhouse, CFO
Mr. Shimon Shushan, Production Manager
Mrs. Yulia Tzirkin, QA Manager
Dr. Gilead Fortuna - Chairman
Dr. Zvi Harel
Mr. Eyal Ginzberg
Dr. Reinhard Effenberger